Adagene Inc.

NASDAQ:ADAG

Biotechnology

Healthcare
$1.82 +3.68%

+$0.13 today

Market cap
$68.52M
Beta
0.59
P/E (TTM)
-7.9
EPS (TTM)
-$0.47
52W Low $1.30High $4.75

Volume 1.30M

Average 0.21M

ADAG EPS (Diluted)

Earnings per share assuming conversion of dilutive securities such as options and convertible instruments.

Adagene Inc.NASDAQ: ADAG

EPS (Diluted) · Q4 FY2025 · quarter ended Dec 2025

EPS (Diluted) remains negative

Q4 FY2025 EPS (Diluted) was -$0.11, compared with -$0.71 a year earlier. Trailing-twelve-month EPS (Diluted) was -$0.9.

Context

  • EPS (Diluted) grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether EPS (Diluted) reaches the consensus estimate from 4 analysts of -$0.54 (-18.3%) for the fiscal year ending Dec 2026, a slowdown from the +51.6% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterDec 2025
-$0.11— QoQ
Last fiscal yearDec 2025
-$0.46+51.6% YoY
LTMJun 2024
-$0.9+14.9% YoY
EPS (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+84.5%——
1 year+51.6%-18.3%-69.8 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EPS (Diluted) history

USD · from the income statement

Latest · FY2025
(0.46) USD
Year-over-year change
+51.6%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EPS (Diluted) vs competitors

How ADAG compares with its peers on the latest reported figures

  • ADAG's LTM Jun 2024 EPS (Diluted) of -$0.9 is the 3rd highest of the 9 companies compared; the peer median is -$1.18.
ADAG Competitors Peer median
EPS (Diluted) for ADAG and competitors
Company Period LTM YoY 3-year CAGR
FBIOFortress Biotech, Inc.LTM Mar 2026$3.18 +235.9%—
GANXGain Therapeutics, Inc.LTM Mar 2026-$0.58 +34.8%—
ADAGAdagene Inc.LTM Jun 2024-$0.9 ——
TCRXTScan Therapeutics, Inc.LTM Mar 2026-$0.96 +11.9%—
OSTXOS Therapies IncorporatedLTM Mar 2026-$1.07 -124.9%—
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026-$1.28 +38.9%—
XBITXBiotech Inc.LTM Mar 2026-$1.32 -2.1%—
NTRBNutriband Inc.LTM Apr 2026-$2.62 -191.1%—
ACETAdicet Bio, Inc.LTM Mar 2026-$14.9 +28.4%—
Peer median (excluding ADAG) -$1.18+20.1%—

Competitors are the stored peer set for ADAG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue10.18M9.29M18.11M103.2K7.67M
Cost of Revenue00000
Gross Profit10.18M9.29M18.11M(823.04K)7.67M
Gross Margin100.0%100.0%100.0%-797.5%100.0%
Research & Development68.1M81.34M36.64M28.78M22.03M
Selling, General & Admin14.44M11.87M8.67M7.27M7.08M
Operating Expenses82.54M93.21M41.83M36.05M29.11M
Depreciation & Amortization1.13M1.43M1.21M926.25K589.79K
EBITDA(69.99M)(77.39M)(14.95M)(31.66M)(16.85M)
EBITDA Margin-687.8%-832.8%-82.5%-30680.5%-219.7%
Operating Income(72.36M)(83.92M)(23.72M)(35.95M)(21.44M)
Operating Margin-711.2%-903.1%-131.0%-34835.4%-279.5%
Interest Income76.17K377.5K4.28M3.8M2.3M
Interest Expense363.76K693.32K1.11M851.87K463.13K
Other Income / Expenses887.77K4.41M6.46M2.51M3.53M
Income Before Tax(71.48M)(79.51M)(17.25M)(33.44M)(17.91M)
Pre-Tax Margin-702.5%-855.6%-95.3%-32403.5%-233.4%
Income Tax Expense1.7M459.06K1.69M(17.55K)(297.86K)
Net Income(73.18M)(79.97M)(18.95M)(33.42M)(17.61M)
Net Margin-719.2%-860.6%-104.6%-32386.4%-229.6%
EPS (Basic)(2.29)(2.31)(0.55)(0.95)(0.46)
EPS (Diluted)(2.29)(2.31)(0.54)(0.95)(0.46)
Weighted Avg Shares32.02M34.65M34.64M36.02M37.76M
Weighted Avg Shares (Diluted)32.02M34.65M35.03M36.02M37.76M

Adagene Inc.

NASDAQ:ADAG

Intrinsic Alpha fair value

Locked

Current Price

$1.82

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.